Last reviewed · How we verify

NCT06020378

Hydroxychloroquine May be Beneficial for Preeclampsia

Active, enrolled Last updated 24 April 2025
What this trial tests

trial testing Hydroxychloroquine in Pre-Eclampsia in 462 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 January 2024
Primary endpoint
1 July 2026
1 December 2026

Quick facts

Lead sponsorRenJi Hospital
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment462
Start date1 January 2024
Primary completion1 July 2026
Estimated completion1 December 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

RenJi Hospital

Who can join

Eligibility, female only, with Pre-Eclampsia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to investigate the impact of hydroxychloroquine on the incidence of hypertensive pregnancy disorders in women with a history of recurrent spontaneous abortion (RSA).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Hydroxychloroquine

Trials testing the same drug.

Other recruiting trials for Pre-Eclampsia

Currently open trials in the same condition.

Other RenJi Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06020378.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing